...
首页> 外文期刊>Current Pharmaceutical Biotechnology >The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell
【24h】

The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell

机译:SB202190和SP600125的药物组合显着抑制耐奥拉帕比的卵巢癌细胞的生长和转移

获取原文
获取原文并翻译 | 示例
           

摘要

Background & Objective: Many targeted ovarian cancer patients are resistant to olaparib treatment. Here we seek to understand the underlying molecular events and search for potential combinational therapeutics to surmount the intrinsic olaparib resistance in human ovarian cancer.
机译:背景与目的:许多靶向卵巢癌患者对奥拉帕尼治疗有抗药性。在这里,我们试图了解潜在的分子事件,并寻找潜在的联合疗法以克服人类卵巢癌固有的奥拉帕尼耐药性。

著录项

  • 来源
    《Current Pharmaceutical Biotechnology》 |2018年第6期|506-513|共8页
  • 作者单位

    Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China;

    Wenzhou Peoples Hosp, Dept Gynecol & Obstet, 57 Canghou St, Wenzhou 325000, Peoples R China;

    Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China;

    Cent Hosp Zibo, Dept Gynecol, 54 Gongqingtuan West Rd, Zibo, Peoples R China;

    Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China;

    Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China;

    Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Olaparib; ovarian cancer; SB202190; SP600125; MAPK; anti-tumor;

    机译:奥拉帕里布;卵巢癌;SB202190;SP600125;MAPK;抗肿瘤;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号